FIRST AIRED: May 23, 2017

Nice work! Enjoy the show!


You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!



now in pharmaceuticals revealing Monday that it was under investigation by the U. S. securities and exchange commission disclosure coming after a while twenty four hours for the embattled pharmaceutical giant which is not a stock plunging Monday trading British reporter Carl down and the first started with an announcement was made on Monday about the company restating twenty sixteen quarter earnings guidance of there's a lot of interest a lot of doubt in the investor community but the sustainability about its business model , politicians are ramping up rhetoric against high drug prices , and people really aren't sure whether or not it would be able to continue growing investors were also digesting news Sunday that the company you know out on medical leave was returning effective immediately that would postpone the release of fourth quarter results , then came the FTC bombshell so far there are no details but all available about the nature of this investigation we have confirmed that this investigation pertains to something new , there've been several publicly revealed in investigations by numerous government body controlling the past so this is yet another wild card for investors , overall the factors contributing to a cloud of uncertainty for the investor community and raising even more questions around a company that has been in the spotlight controversy since October when short seller into left , suggested that valiant pharmaceutical patent unethical relationship with a distributor called billet or looted investors service place the rating valiant under review for downgrade reflecting concerns that the company operating performance is weaker than it expectations